SCHEMBL2831397

SCHEMBL2831397

Cc1ccccc1OC(=O)c1ccccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.54
ALDH1A1 P00352 2/20 0.53
ESR1 P03372 2/20 0.51
ESR2 Q92731 2/20 0.51
MEN1 O00255 1/20 0.51
MAPT P10636 5/20 0.50
LMNA P02545 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 1/20 0.50
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
POLB P06746 2/20 0.47
KDM4E B2RXH2 1/20 0.46
CYP2C9 P11712 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HPGD P15428 1/20 0.46
PKM P14618 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833933 0.89 KMT2A (0.57) KMT2AALDH1A1ESR1ESR2MEN1
SCHEMBL30607253 0.87 ESR1 (0.58) KMT2AALDH1A1ESR1ESR2MEN1
SCHEMBL5150486 0.87 ESR1 (0.58) KMT2AALDH1A1ESR1ESR2MEN1
SCHEMBL10457215 0.85 KMT2A (0.66) KMT2AALDH1A1ESR1ESR2MEN1
SCHEMBL2833886 0.85 KMT2A (0.56) KMT2AALDH1A1ESR1ESR2MEN1
SCHEMBL2838173 0.85 KMT2A (0.49) KMT2AALDH1A1ESR1ESR2MEN1
SCHEMBL2833936 0.84 MAPT (0.56) KMT2AALDH1A1ESR1ESR2MAPT
SCHEMBL8431592 0.83 KMT2A (0.68) KMT2AALDH1A1ESR1ESR2MEN1
SCHEMBL2838181 0.83 KMT2A (0.67) KMT2AESR1ESR2MEN1LMNA
SCHEMBL4394455 0.81 HSD17B10 (0.56) KMT2AALDH1A1ESR1ESR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 KMT2A 1023/4885ALDH1A1 2511/4885ESR1 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.